Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Satsuma Pharmaceuticals, Inc. (STSA) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/12/2023 4 RA CAPITAL MANAGEMENT, L.P. (Former 10% Owner) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Unknown transaction of 5,914,252 shares @ $0
Disposed/sold 10,000 options to buy @ $26.99, valued at $269.9k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
06/12/2023 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Satsuma Pharmaceuticals, Inc.
06/09/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/09/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/09/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/08/2023 4 O'Neil Thomas P. (CFO) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Unknown transaction of 13,877 shares @ $0.91, valued at $12.6k
Disposed/sold 60,000 options to buy @ $29, valued at $1.7M
Disposed/sold 80,000 options to buy @ $4.6, valued at $368k
Disposed/sold 190,000 options to buy @ $3.46, valued at $657.4k
Disposed/sold 72,340 options to buy @ $4.56, valued at $329.9k
Disposed/sold 76,595 options to buy @ $1.04, valued at $79.7k
06/08/2023 4 Shah Rajeev M. (10% Owner) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Unknown transaction of 5,914,252 shares @ $0.91, valued at $5.4M
Disposed/sold 10,000 options to buy @ $26.99, valued at $269.9k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
06/08/2023 4 TAKANASHI KEN (10% Owner) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Bought 22,053,581 shares @ $0.91, valued at $20.1M
Disposed/sold 10,000 options to buy @ $26.99, valued at $269.9k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
06/08/2023 4 Riebe Michael T (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Disposed/sold 10,000 options to buy @ $26.99, valued at $269.9k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
Disposed/sold 14,893 options to buy @ $4.56, valued at $67.9k
Disposed/sold 12,765 options to buy @ $1.04, valued at $13.3k
Disposed/sold 12,765 options to buy @ $0.9, valued at $11.5k
06/08/2023 4 Sandoval Elisabeth (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Disposed/sold 10,000 options to buy @ $26.99, valued at $269.9k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
Disposed/sold 14,893 options to buy @ $4.56, valued at $67.9k
06/08/2023 4 Soloway Thomas P (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Disposed/sold 20,000 options to buy @ $27.25, valued at $545k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
06/08/2023 4 Kollins John A (President and CEO) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Unknown transaction of 305,911 shares @ $0.91, valued at $278.4k
Disposed/sold 175,000 options to buy @ $29, valued at $5.1M
Disposed/sold 240,000 options to buy @ $4.6, valued at $1.1M
Disposed/sold 505,000 options to buy @ $3.46, valued at $1.7M
Disposed/sold 276,595 options to buy @ $4.56, valued at $1.3M
Disposed/sold 127,659 options to buy @ $1.04, valued at $132.8k
Disposed/sold 127,659 options to buy @ $0.9, valued at $114.9k
06/08/2023 4 Lukatch Heath (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Disposed/sold 20,000 options to buy @ $27.97, valued at $559.4k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
06/08/2023 4 KING THOMAS BRAXTON (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Disposed/sold 10,000 options to buy @ $26.99, valued at $269.9k
Disposed/sold 20,000 options to buy @ $4.6, valued at $92k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
Disposed/sold 14,893 options to buy @ $4.56, valued at $67.9k
Disposed/sold 12,765 options to buy @ $1.04, valued at $13.3k
Disposed/sold 12,765 options to buy @ $0.9, valued at $11.5k
06/08/2023 4 Shin Nippon Biomedical Laboratories, Ltd. (10% Owner) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Bought 22,053,581 shares @ $0.91, valued at $20.1M
Bought 8,423,732 shares @ $0.91, valued at $7.7M
06/08/2023 4 Harsch Mutya (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.
Txns: Disposed/sold 40,000 options to buy @ $4.48, valued at $179.2k
Disposed/sold 30,000 options to buy @ $3.46, valued at $103.8k
06/08/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/08/2023 SC 13D/A Shin Nippon Biomedical Laboratories, Ltd. reports a 100% stake in SATSUMA PHARMACEUTICALS, INC.
06/08/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/08/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
06/08/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/08/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Fifth Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company"
06/08/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
06/08/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
05/26/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
05/18/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
05/18/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
05/18/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Satsuma Pharmaceuticals Announces FDA Acceptance of 505 NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy